Back

Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate

30 August 2016 (15:51 - 16:00)
Organised by:
Congress Presentation Part of: Lipid-lowering agents - New perspectives Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Associate Professor Michael Blazing

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study
Professor S. Yamashita (Izumisano, JP)
Abstract Slides
Presentation thumbnail
A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C
Doctor S. Shah (Rahway, US)
Abstract Slides
Presentation thumbnail
Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-beta HDL-mimetic, across the clinical development programs
Professor A. Corsini (Milan, IT)
Abstract Slides
Presentation thumbnail
Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials
Doctor M. Kolodziejczak (Bydgoszcz, PL)
Abstract Slides
Presentation thumbnail
Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction: a nationwide cohort study
Doctor T. Sehested (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Lipid-lowering agents - New perspectives

The Event

Event poster

ESC Congress 2016

30 August 2016 15:51 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources